We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Automated Nucleated Red Blood Cell Enumeration Evaluated

By LabMedica International staff writers
Posted on 17 Jun 2015
The enumeration of nucleated red blood cell (NRBC) has been evaluated on a new automated hematology analyzer and to demonstrate the precision compared to manual counts (MC) at the various NRBC values.

The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.

Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. More...
These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.

The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.

In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.

The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.

Related Links:

Mahidol University 
Sysmex Corporation 



New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.